Beyond weight loss, the expanding therapeutic landscape of GLP-1 agonists now includes cardiovascular risk reduction, peripheral artery disease management, and active clinical trials for neurodegenerative disorders and substance use disorderswith over 15 global trials underway for the latter indication alone
In midlife, womens weight is tied to shifting sex hormones, gut peptide function, nutrient status, nervous system load, inflammation, and life experiences
studying different planning approaches and their effectiveness in addressing particular planning themes
In practice, obesity medications face systematic exclusion from most provincial formularies
Olcotts extensive PBM experience includes utilization management, formulary development, clinical program development, and maintaining client relationships